Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

By S. Loibl, J. O’Shaughnessy, M. Untch, W. Sikov, H. Rugo, M. McKee, J. Huober, M. Golshan, G. von Minckwitz, D. Maag and 9 more. The Lancet Oncology, 2018

650 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/701598bbb78e891e6075aafccf0ca5d69b115deb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Lisa A. Carey
2. C. Lord

In Genetics

1. Yuxing Liao
2. C. Lord

In Oncology

1. Yongheng Chen
2. S. Leonov
3. Huajun Zhang
4. Lin Chen
5. Na Liu
6. C. Lord
7. Yun R Li
8. Yulia Merkher

Citations in the corpus

• WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics (2024, methodology): “Differential gene expression data from resistant versus sensitive breast tumors in the BrighTNess trial’s veliparib treatment arm ( 28 ), downloaded from ClinicalOmicsDB ( 27 ), were used for enrichment against the KEGG database.”
• A decade of clinical development of PARP inhibitors in perspective (2019, background): “Conversely, veliparib, which has lower trapping potency, has not demonstrated significantly increased antitumour activity when combined with neoadjuvant platinumbased chemotherapy [40].”
• Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, methodology): “The randomized phase II and III trials included in the review are summarized in the Data Supplement Table 1 (online only).(9-25,26-55) The included RCTs addressed the use of neoadjuvant systemic therapy in patients with high-risk HER2-positive or TNBC; specific neoadjuvant systemic therapy regimens ”
• Recent advances in therapeutic strategies for triple-negative breast cancer (2022, background): “In 2018, a related phase III trial of veliparib–carboplatin in TNBC (NCT02032277) was reported [35].”